Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada. Show more

Location: 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, H4M 2X6, Canada | Website: https://www.milestonepharma.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

173.7M

52 Wk Range

$0.63 - $3.06

Previous Close

$2.19

Open

$2.18

Volume

6,360,955

Day Range

$1.98 - $2.19

Enterprise Value

148.4M

Cash

82.59M

Avg Qtr Burn

-10.78M

Insider Ownership

3.36%

Institutional Own.

50.83%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CARDAMYST (Etripamil) Details Paroxysmal supraventricular tachycardia	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Etripamil (calcium channel blocker) Details Atrial fibrillation	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Etripamil (calcium channel blocker) Details Angina, Coronary artery disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.